GPBAR1 and Obesity: It has been demonstrated that treatment of db/db mice, a genetic model for obesity with MAFLD, with a dual FXR/TGR5 agonist improves liver histology and increases M2 macrophage markers in liver while a selective TGR5 agonist had similar beneficial effects in high fat diet induced MAFLD in mice.